Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics, Inc. announced that the first patient with systemic lupus erythematosus has been treated in the Phase I autoimmunity study of FT819, the company’s off-the-shelf, CD19-targeted chimeric antigen receptor T cell program.